Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 167.00
Bid: 167.00
Ask: 169.00
Change: -2.00 (-1.18%)
Spread: 2.00 (1.20%)
Open: 170.00
High: 174.00
Low: 167.00
Yest. Close: 169.00
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AGM, EGM Calendar - Week Ahead

15 Jun 15 14:52

Synairgen Swings To 2014 Pretax Profit On AstraZeneca Licence Deal

3 Mar 15 08:38

Tuesday broker round-up UPDATE

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating. Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy reco

21 Oct 14 08:50

Synairgen Swings To Profit On Transformational AstraZeneca Deal

25 Sep 14 11:03

Synairgen raises funds to develop AstraZeneca drug

Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is

4 Jul 14 12:11

UK MORNING BRIEFING: William Hill Promotes From Within

4 Jul 14 07:21

Synairgen Raises GBP5.3 Million In Share Placing At 50 Pence

4 Jul 14 06:47

Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property

Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff

15 Jun 14 12:28

MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions

LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company <strong>BG Group</strong> leading the gains as the price of oil climbed amid escalating violence in Iraq.<br /><br /

12 Jun 14 16:37

TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014

LONDON (Alliance News) - The following is a summary of top news stories Thursday.<br />----------<br /><strong>COMPANIES</strong><br />----------<br />The initial public offering of <strong>B&amp;M European Value Retail</strong> SA, the discount retailer chaired by former<strong> Tesco</strong

12 Jun 14 10:23

London open: Mining stocks pull FTSE 100 lower ahead of data

- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound

12 Jun 14 08:25

AstraZeneca signs licence deal with Synairgen

British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de

12 Jun 14 07:42

UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen

LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight. <br /><br /><strong>AstraZeneca</strong> is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology

12 Jun 14 07:36

AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen

LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections

12 Jun 14 06:52

Synairgen Pretax Loss Narrows On Expenses

LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye

20 Mar 14 12:47

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.